Research progress of endothelial lipase as a therapeutic target for coronary heart disease

Abstract

Endothelial lipase(EL) is mainly generated by vascular endothelial cells and is responsible for regulating liver lipid metabolism and intestinal lipid absorption. In the inflammatory state, EL can also promote the adhesion and aggregation of macrophages and platelets in the damaged vascular endothelium. EL can also promote the proliferation of damaged vascular endothelial cells, and inhibit the over-expression of EL can reduce the degree of atherosclerosis. However, in acute coronary artery disease and oxidative stress reaction, EL can enhance the antioxidant capacity of high-density lipoprotein cholesterol, reduce the damage of inflammatory reaction to vascular endothelium, enhance the energy metabolism of damaged cardiomyocytes and inhibit apoptosis of damaged cardiomyocytes. As a new therapeutic drug for dyslipidemia and atherosclerosis, endothelial lipase inhibitor needs more extensive clinical trials to clarify its true clinical efficacy, safety and specific clinical application scenarios.

Keywords

• endothelial lipase|lipid metabolism|inflammatory reaction|atherosclerosis|coronary heart disease (chd)